Across TCGA pan-cancer cohorts, SLC40A1 mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of SLC40A1’s most consistent transcriptional readouts.
The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where SLC40A1 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types SLC40A1 is over-expressed in tumor, although a few such as LSCC and LUAD show the opposite, repressed pattern.
CCRCC, LSCC, and LUAD are the cancer types where SLC40A1 tumor–normal differential expression is most reproducible.